Oncodesign Precision Medicine Obtains Deep Tech Development Funding for Its ANIMUS Program

Regulatory News:

Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63 ; Mnemonic : ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancer, announces today that it has received notification of the allocation of financial support from the Deep Tech Development Fund.

The funding is granted through a combination of grants and a repayable advance to finance R&D investment. This support is financed by the French government with funds from the Programme d'Investissement d'Avenir (PIA4) or the Fonds pour l'Innovation et l'Industrie (FII),and aims to finance the research and development phases of breakthrough innovation, prior to its industrial and commercial launch.

The ANIMUS program (Ai-boosted NanocyclIx platforM drUg diScovery) is based on the development of proprietary methods using Artificial Intelligence to accelerate the optimization of molecules developed using our Nanocyclix technology, in order to select drug candidates faster. The ANIMUS program is supported exclusively by OPM.

OPM has currently a unique Nanocyclix macrocycle collection of over 12,000 molecules, all of which are kinase inhibitors. Having carried out extensive characterization of these molecules, OPM now has an annotated database that is unique in the industry, which is an exclusive asset for applying Machine Learning and Deep Learning methods to optimize the Drug Discovery process.

The main purpose of ANIMUS is to develop proprietary technologies to improve the efficiency of the drug discovery process at OPM, based on Nanocyclix technology. This involves the development of AI approaches enabling, first, the systematic optimization of all parameters at each DMTA¹ cycle in order to reduce the number of cycles required to identify drug candidates and, second, the use of NCX generative molecule design to assess a very large number of molecules in silico at the design phase.

The Deep Tech Development Fund has awarded €745,000 to ANIMUS for a total project cost of €1.49 million and a 36-month project period.

Philippe Genne, Chairman and CEO of Oncodesign Precision Medicine, said: “Following the recent allocation of ERDF funding for the COMETE project, which should enable us to start developing our first systemic therapy products, we are delighted to have been granted Deeptech funding focused on our Nanocyclix technology. AI is a technology that is now essential for effectively optimizing the Drug Discovery process. We initially integrated it in OncoSNIPER for the discovery of new therapeutic targets, and in Nanocyclix the aim is to achieve more rapidly the development of more powerful and specific kinase inhibitors. We are capitalizing on our 15 years of R&D to develop Nanocyclix, its library and our AI skills. These projects are key to our technological development and the construction of our Precision Medicine platform. This funding is another strong recognition of invaluable support from our regional institutional environment and it highlights the dynamic behind the development of biotechnologies and, in particular, Precision Medicine in the Bourgogne Franche Comté region.”